Wilson Therapeutics appoints Vincent Metzler as Vice President Commercial Planning & Launch Strategy
Wilson Therapeutics AB (publ), announces the appointment of Vincent Metzler as Vice President Commercial Planning & Launch Strategy. Dr Metzler will report to CEO Jonas Hansson and will join the company’s management team.
Dr Metzler is a senior marketing & commercial operations executive with an extensive rare disease background and more than 16 years of experience in the pharmaceutical and biotech industries. Most recently Dr Metzler served as Senior Director Marketing at Alexion where he was responsible for and played an instrumental role in launching and building the commercial success of Soliris in the EMEA region. Soliris is the world’s most successful non-oncology orphan product with more than $2.5 billion in world-wide sales in 2015. At Alexion Dr Metzler developed and implemented the marketing strategy for 7 of the largest markets in the global Soliris business and he was a core member of the Global Soliris Leadership Team. Prior to Alexion Dr Metzler held various sales and marketing positions at Miltenyi Biotec, Roche and Amgen. Dr Metzler received his MSc in Chemistry & Biology from Louis Pasteur University in Strasbourg and his PhD in Molecular Biology from the University of Bern.
“I am very excited to join Wilson Therapeutics,” said Vincent Metzler. “With my strong passion for bringing innovative medicines to patients suffering from rare diseases, I see this as a unique opportunity to make our highly promising product candidate available to patients affected by the debilitating Wilson Disease who still are in significant need for effective and well-tolerated treatment options.”
“I am very pleased to welcome Vincent to our executive team,” said Jonas Hansson, CEO of Wilson Therapeutics. “Vincent brings a wealth of global marketing & commercialization expertise in the rare disease field with a proven track record, having been responsible for the commercial success of Soliris in Europe. His knowledge and experience will be tremendously valuable for us as we prepare for a future potential launch of Decuprate®.”
About Wilson Therapeutics
Wilson Therapeutics is a biopharmaceutical company, based in Stockholm, Sweden, that develops novel therapies for patients with rare diseases. Wilson Therapeutics’ lead product, Decuprate®, is initially being developed as a novel treatment for Wilson Disease and is currently being evaluated in a Phase II clinical study. Wilson Therapeutics is listed in the Mid Cap segment on Nasdaq Stockholm with the stock ticker WTX.
Visit www.wilsontherapeutics.com for more information.
For further information contact:
Jonas Hansson, CEO, Wilson Therapeutics AB
Telephone: +46 8 796 00 00
Wilson Therapeutics AB (publ)
Org nr 556893-0357
Västra Trädgårdsgatan 15
SE-111 53 Stockholm
The information in the press release is information that Wilson Therapeutics is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above, at 08.30 CET on August 15, 2016.